Chimeric Antigen Receptor (CAR) T-cell Therapy | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its CAR T-cell therapy coverage policy, effective May 15, 2026. Here's what billing teams need to do before that date.

CAR T-cell therapy billing has never been simple. The Centers for Medicare & Medicaid Services modified its Chimeric Antigen Receptor (CAR) T-cell therapy coverage policy, and the effective date of May 15, 2026 is close enough that your billing team needs to act now. This policy does not carry a numbered policy code in the CMS system, but that doesn't make it any less binding. The full policy text is available through PayerPolicy's source document, and the changes touch on medical necessity criteria, prior authorization requirements, and reimbursement conditions for one of the most financially significant therapies in oncology billing today.

One more thing before the details: the policy document does not list specific CPT or HCPCS codes. You'll see why that matters in the coding section below.

Quick-Reference Table

CMS CAR T-Cell Therapy Coverage Criteria and Medical Necessity Requirements 2026

CAR T-cell therapy sits at the top of the reimbursement exposure chart for any oncology or hematology program billing Medicare. A single infusion event can generate a claim in the hundreds of thousands of dollars. When CMS modifies the coverage policy governing this therapy, every word of that change matters.

The full detail of the modified criteria is housed in the source policy document. Because no structured policy summary was available at the time of writing, the specific updated language around medical necessity is not reproduced here. That's not a reason to wait—it's a reason to pull the source document now and read it against your current workflows.

What the CMS CAR T-cell therapy coverage policy has historically required, and what your team should verify still applies under the modified version, includes the following. Medicare covers CAR T-cell therapy when it is FDA-approved for the specific indication being treated. The patient must have a confirmed diagnosis that matches an approved indication in the product labeling. Treatment must occur at a facility enrolled in the FDA-required Risk Evaluation and Mitigation Strategy (REMS) program for the specific CAR T-cell product being administered.

Medical necessity documentation is the linchpin here. CMS requires that the medical record show prior lines of therapy, the patient's current disease status, and the treating physician's determination that the patient is an appropriate candidate. If your documentation doesn't answer those questions before the claim goes out, you're looking at a claim denial.

Prior authorization requirements for CAR T-cell therapy vary by Medicare Advantage plan and by Medicare Administrative Contractor (MAC) region. Fee-for-service Medicare does not require prior authorization for CAR T-cell therapy the way commercial payers do—but that does not mean you can skip the documentation step. Your MAC may have a local coverage determination (LCD) that layers additional requirements on top of the national policy. Check your MAC's LCD before May 15, 2026.

CMS CAR T-Cell Therapy Exclusions and Non-Covered Indications

CMS does not cover CAR T-cell therapy when it is used off-label—meaning for an indication not included in the FDA-approved labeling for that specific product. This is where billing teams get tripped up most often.

Each CAR T-cell product has its own FDA approval. Axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel each carry distinct approved indications. Using one product's billing pathway for a diagnosis covered only under another product's label is a fast route to a claim denial and a potential overpayment situation.

CMS also does not cover CAR T-cell therapy administered at a facility that is not enrolled in the applicable REMS program. This isn't a gray area—it's a hard exclusion. If your facility's REMS enrollment has lapsed or if you're billing for a product your facility isn't certified to administer, the claim will not hold up.

Investigational use of CAR T-cell therapy outside of a CMS-approved clinical trial framework is also not covered under the standard coverage policy. Coverage with Evidence Development (CED) conditions may apply in some circumstances—confirm this with your compliance officer if you're billing for patients enrolled in trials.

Coverage Indications at a Glance

Note: The modified policy document does not provide a structured indication-by-indication breakdown in the data available at publication. The table below reflects CMS's established framework for CAR T-cell therapy coverage, which your team should verify against the updated May 15, 2026 policy text.

CMS CAR T-Cell Therapy Billing Guidelines and Action Items 2026

CAR T-cell therapy billing is high-stakes and low-margin for error. Here's what your team needs to do before May 15, 2026.

CPT, HCPCS, and ICD-10 Codes for CAR T-Cell Therapy Under This CMS Policy

The policy document associated with this modification does not list specific CPT, HCPCS, or ICD-10 codes. This is not unusual for CMS policy modifications—the coding framework is maintained separately through OPPS quarterly updates, the Medicare Physician Fee Schedule, and CMS transmittals.

Do not infer codes from this post alone. Your coding team should reference the current HCPCS Level II code set and any active CMS transmittals governing CAR T-cell infusion billing. CMS has historically used specific HCPCS Q-codes for individual CAR T-cell products—these are product-specific, not interchangeable.

Work with your coding team and verify the active codes through CMS's official HCPCS code lookup or your coding software's current update. Using an outdated or incorrect code on a CAR T-cell claim is one of the most common reasons these high-dollar claims end up in a denial queue.

If you're unsure which codes apply to your specific patient population and product mix, this is exactly the situation where your billing consultant or coding compliance team earns their fee. Get that conversation scheduled before May 15, 2026.